Literature DB >> 6886283

The use of reserpine for elderly hypertensive patients.

J Luxenberg, L Z Feigenbaum.   

Abstract

Antihypertensives are among the most commonly prescribed drugs for the elderly. Several studies have discussed the benefits of stepped-care drug therapy for hypertension in the elderly, and propranolol, methyldopa, and more recently, clonidine and prazosin have been recommended as step-two antihypertensive drugs. Recent articles omit reserpine as an alternative. A case is made for the use of reserpine by comparing factors of special importance to most elderly: cost, side-effects, frequency of dosage, number of tablets, and the effect of omitted doses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6886283     DOI: 10.1111/j.1532-5415.1983.tb02201.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  7 in total

Review 1.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

2.  Reserpine as monotherapy for mild hypertension?

Authors:  L Z Feigenbaum
Journal:  West J Med       Date:  1991-06

3.  Carbon monoxide poisoning.

Authors: 
Journal:  West J Med       Date:  1991-06

4.  The treatment of hypertension in the elderly.

Authors:  M Chellingsworth; D G Beevers
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

Review 5.  Polypharmacy: the cure becomes the disease.

Authors:  C A Colley; L M Lucas
Journal:  J Gen Intern Med       Date:  1993-05       Impact factor: 5.128

6.  Reserpine and thiazide for hypertension--an inexpensive therapy for older patients.

Authors:  L Z Feigenbaum
Journal:  West J Med       Date:  1993-05

7.  Ajmalicine and Reserpine: Indole Alkaloids as Multi-Target Directed Ligands Towards Factors Implicated in Alzheimer's Disease.

Authors:  Priya Kashyap; Vivekanandan Kalaiselvan; Robin Kumar; Suresh Kumar
Journal:  Molecules       Date:  2020-04-01       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.